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Identity 
Other names: BCH, BHC, NK-2, NKX2.1, NKX2A, 
TEBP, TITF1, TTF-1, TTF1 




NKX2-1 is regulated by two promoter regions: the first 
one is located in intron 1 (5' of exon 1, regulation of 
NKX2-1 in lung and thyroid cells).  
The second one is situated in the 5' flanking region of 
exon 1, it is a 330 bp TATA-less region containing 
multiple palindromes and G/C-rich elements. It 
regulates NKX2-1 in lung epithelial cells responding to 
transcription factors sp1 and sp3. 
Transcription 
NKX2-1 is transcribed in two highly conserved forms: 
mRNA-isoform 1 contains exon 1, exon 2, and exon 3, 
it is translated into a 401 amino acid protein and 
represents the minor transcript. mRNA-isoform 2 is the 
predominant transcript containing exon 2 and exon 3. It 
is translated into a 371 aa protein. 
  
Figure 1. NKX2-1 gene and NKX2-1 mRNA. 
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The NKX2-1 protein includes three functional 
domains: an N-terminal transactivation domain, a 
DNA-binding transactivation domain and a C-terminal 
transactivation domain. 
Expression 
In the lung, expression of NKX2-1 is consistent 
throughout all life stages from fetal to adult tissue. It is 
expressed in conducting airways type II alveolar 
epithelial cells and Clara cells and uniformly in the 
terminal respiratory unit. 
NKX2-1 expression is also found in thyroid follicular 
cells and both normal and hyperplastic C cells where it 
activates calcitonin gene expression. 
NKX2-1 is not expressed in adult neurons of the basal 
ganglia.  
During embryonic and fetal development, NKX2-1 
expression is found in various tissues (e.g. brain, lung, 
thyroid), for details see "function" → "Embryonic and 
fetal development". 
Localisation 
NKX2-1 is a nuclear transcription factor. 
Function 
In the lung, NKX2-1 regulates the expression of the 
lung-specific genes: surfactant protein SP-A, SP-B, SP-
C and Clara cell secretory protein (CCSP). 
It cooperates with C/EBPalpha in transactivating 
CCSP. 
In the transcription of SP-C, NKX2-1 interacts with 
nuclear factor I to differentially regulate the 
transcription. The longer NKX2-1 isoform reduces 
transactivation of SP-C, probably due to some kind of 
interference. 
NKX2-1 is a key activator of SP-B gene expression 
having at least two binding sites at the SP-B promoter 
and enhancer. The transactivation capacity of NKX2-1 
regarding the expression of SP-B is controlled by the 
sphingolipid ceramide which is produced in 
inflammation and reduces NKX2-1 binding capacity to 
the SP-B promoter. SP-B transcription is also inhibited 
by TGFbeta1-mediated interaction of smad3 with 
NKX2-1. Moreover, NKX2-1 interacts with retinoic 
acid receptor (RAR), nuclear receptor coactivators 
(p160, CBP/p300) and signal transducers and activators 
of transcription 3 (STAT3) in regulation of SP-B 
expression. 
Furthermore, NKX2-1 regulates the expression of the  
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secretoglobulin 3A2 gene (SCGB3A2) in mouse 
airways in cooperation with CAATT/enhancer binding 
proteins alpha and delta as well as the expression of 
ABCA3 which encodes for a lipid transporter critical 
for surfactant function at birth and formation of 
lamellar bodies. 
NKX2-1 also plays an important role in the endocrine 
system: it regulates the expression of the thyroid-
specific genes thyroglobulin, thyroid peroxidase, 
thyrotropin receptor and sodium-iodide-symporter, 
therefore being crucial for proper thyroid hormone 
synthesis. 
Deletion of NKX2-1 in differentiated neurons of the 
hypothalamus in mice causes delayed puberty, reduced 
reproductive capacity and a shorter reproductive span 
in female mice, suggesting that NKX2-1 plays an 
important role in juvenile and adult endocrine function. 
During embryonic and fetal development, NKX2-1 is 
active in various organs, especially lung, thyroid and 
brain. 
As a crucial factor for lung development, NKX2-1 is 
expressed in the ventral foregut endoderm at a very 
early stage functioning as a signal which is essential for 
specification of a pulmonary cell fate instead of a liver 
cell fate. At a later stage, NKX2-1 is critical to the 
formation of distal pulmonary structures (whereas 
proximal lung differentiation is NKX2-1-independent), 
a function in which it is inhibited by TGF-beta. 
In addition to that NKX2-1 regulates surfactant protein 
genes that are important for the development of 
alveolar stability at birth. It induces SP-A gene 
expression in fetal lung type II cells through increased 
binding of NKX2-1 (mediated by cAMP) and the 
NFkappa-B proteins p50 and p65. Supporting the 
notion of NKX2-1-dependent SP-expression, lung and 
associated respiratory dysfunction in neonates caused 
by SP-B-deficiency are partly induced by down-
regulation of NKX2-1. The main therapeutical option, 
prenatal glucocorticoid treatment, induces the 
expression of NKX2-1. NKX2-1 regulates expression 
of uteroglobin-related protein-1 and claudin-18 during 
lung development. 
During thyroid gland organogenesis NKX2-1 is 
expressed in the ultimobranchial body (UBB) and in 
the thyroid diverticulum. It is important for the survival 
of UBB-cells and eventually their dissemination into 
the thyroid diverticulum and for the formation of the 
UBB-derived vesicular structure. Pendrin and 
thyroglobulin are downstream targets of NKX2-1 
during thyroid differentiation. The transactivational 
activity of NKX2-1 during thyroid development can be 
inhibited by NKX2-5. 
In the course of brain development, NKX2-1 
expression is found in both telencephalic and 




pattern the ventral telencephalon. Lack of functional 
NKX2-1 protein in neurons impairs developmental 
differentiation and organization of basal ganglia and 
basal forebrain. NKX2-1 upregulates the transcription 
of nestin, an intermediate filament protein expressed in 
multipotent neuroepithelial cells, by direct binding to a 
HRE-CRE-like site (NestBS) within a CNS-specific 
enhancer, which indicates that nestin might be at least 
one of the effectors of NKX2-1 during forebrain 
development. 
NKX2-1 expression occurs in neurons of the arcuate 
nucleus of the hypothalamus and in glia cells 
(tanycytes) in neonatal and adult mice, as well as in 
fetal and adult pituicytes suggesting that NKX2-1 is 
essential for proper development of the hypothalamus. 
Lack of NKX2-1 causes aberrant trajectory of the 
dopaminergic pathway in the developing hypothalamus 
(mouse-model), development of GABAergic and 
cholinergic neurons is also impaired in NKX2-1 
defective mice. Furthermore, NKX2-1 regulates the 
specification of oligodendrocytes and controls the 
postmitotic migration of interneurons originating in the 
medial ganglionic eminence to either the cortex 
(downregulation of NKX2-1) or the striatum 
(maintenance of NKX2-1 expression and thus direct 
transcriptional activation of neuropilin-2, a guidance 
receptor in postmitotic cells). By directly activating 
Lhx6 during embryonic development NKX2-1 plays an 
essential role for the specification of cortical 
interneurons which express parvalbumin or 
somatostatin.  
In accordance with the findings concerning the role of 
NKX2-1 in the development of the above-mentioned 
organs, NKX2-1-defective mice die at birth due to a 
characteristic set of malformations and functional 
impairments: hypoplastic lungs and insufficient 
surfactant production, defective hypothalamus, absence 
of thyroid and pituitary gland, delayed development of 




Mutations in NKX2-1 (for details see table 1) can cause 
benign hereditary chorea (BHC, a dyskinesia, i.e. a 
neurological disorder characterized by abnormal 
involuntary movements) and brain-lung-thyroid 
syndrome (in addition to BHC, patients suffer from 
congenital hypothyroidism and infant respiratory 
distress syndrome).  
A heterozygous substitution at position 1016 in the 
coding sequence (C → T) leads to a mutant NKX2-1 
protein (A339V) and can contribute to a predisposition 
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Brain-lung-thyroid syndrome 
congenital hypothyreoidism, infant respiratory distress syndrome, benign hereditary chorea 
SNP bp 523 G → T premature stop codon at postition 175 
SNP bp 609 C → A premature stop codon at position 145 
SNP bp 1320 C → A premature stop codon at position 75 
SNP bp 2626 G → T 




site of intron 2 
A → T altered mRNA structure => incorrect removal of introns 
Deletion 14q11.2-q13.3   
Insertion bp 2595  
insertion of GG frameshift mutation: causes truncated protein lacking 
the entire third helix of the homeodomain 
Cancer predisposition 
can contribute to predisposition for multinodular goiter and papillary thyroid carcinoma. 
SNP bp 1016 
C → 
T 
missense mutation: A339V 
Table 1. Mutations in NKX2-1 gene. 
 
For other heterozygous NKX2-1 mutations in humans, 
phenotypes vary widely. 
Thyroid dysfunction ranges from mild 
hypothyrotrophinaemia to severe congenital 
hypothyroidism due to thyroid hypoplasia or even 
agenesis. Implication of the lung ranges from a slight 
increase in pulmonary infections to severe neonatal 
respiratory distress syndrome. 
Homozygous NKX2-1 mutations in humans are 




NKX2-1 expression has been found in a variety of 
tumor entities, especially lung and thyroid tumors (for 
details see table 2). 
Lung neoplasms 
Disease 
NKX2-1 is strongly expressed in 75-90% of primary 
lung adenocarcinomas, whereas only 1/4 of 
bronchioloalveolar carcinomas show NKX2-1 
positivity. Among non-small cell lung cancers, NKX2-
1 is not expressed in squamous cell lung cancer. 
Small cell lung cancer, as well as pulmonary carcinoids 
and non-neuroendocrine large-cell carcinomas partly 
exhibit NKX2-1 protein expression. 
Prognosis 
Overall, NKX2-1 expression is a predictor for better 
survival in adenocarcinomas of the lung (just one 
smaller study suggested that NKX2-1 expression is 
associated with poor prognosis). Controversially, 
NKX2-1 pathway activation in lung cancers is 
associated with poor survival and cisplatin resistance if 
PAX9 or Nkx2-8 pathways are activated at the same 
time. 
Oncogenesis 
NKX2-1 is highly amplified in 5-15% of primary lung 
adenocarcinomas. In cells harbouring NKX2-1 
amplification, this recurrent gene amplification seems 
to be a mechanism of high-level NKX2-1 expression. 
For a subset of lung adenocarcinomas (especially those 
which are derived from the terminal respiratory unit) 
sustained expression of NKX2-1 has been shown to be 
crucial for the survival of tumor cells. In these tumors 
RNAi inhibition of NKX2-1 induces proliferation 
inhibition, growth inhibition and apoptosis (lineage-
specific dependency model). 
Interestingly, NKX2-1 is also an activator of HOP 
(Hsp70/Hsp90 Organizing Protein), a potential tumor 
suppressor gene in lung cancer, and it inhibits EMT 
(epithelial to mesenchymal transition). NKX2-1 
restores epithelial phenotypes in lung adenocarcinomas, 
acting as an adversary of the EMT-stimulating TGF-
beta and a suppressor of tumor progression and 
invasiveness. TGF-beta inhibits the expression of 
NKX2-1 and thus lung morphogenesis. 




Well-differentiated thyroid follicular cell tumors, such 
as follicular adenomas, follicular carcinomas and 
papillary carcinomas exhibit strong nuclear positivity 
for NKX2-1 staining. In contrast, undifferentiated 
thyroid carcinomas show low or no immunoreaction. 
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 Consistently expressed Occasionally expressed Not expressed 
Thyroid  
- Papillary carcinoma  
- Follicular carcinoma  
- Medullary carcinoma  
- Hurthle cell carcinoma 
- Follicular adenoma  
- Hyperplastic follicular cells  
 
- Undifferentiated thyroid 
carcinomas  
Lung  
- Adenocarcinoma  
- Small cell lung cancer 
(SCLC) 
- Pleural effusions of SCLC 
- Pulmonary sclerosing 
hemangioma 
- Bronchioloalveolar 
carcinoma (except for 
mucinous parts) 
- Non-neuroendocrine large-
cell carcinoma  
- Signet-ring cell carcinomas 
of lung origin 
- Pulmonary carcinoids 
(50%)  
- Squamous cell lung cancer 
- Pleural mesothelioma  
- Bronchioloalveolar 
carcinomas (just mucinous 
parts) 
- Basaloid carcinoma of the 
lung  
Gastrointestinal system  
- Small cell cancer of the 
esophagus  
- Colorectal carcinoma  
Genitourinary system  
- Small cell carcinoma of 
the urine bladder  
- Nephroblastoma  
- Endometrial carcinoma  
- Endocervical carcinoma  
 
Thymus    
- Thymic carcinoma  
- Thymoma  
Skin   - Merkel cell carcinoma  
Neuroectodermal   
- Ependymoma  
- Glioblastoma  
- Astrocytoma  
- Oligodendroglioma  
- Medulloblastoma  







carcinoids, large cell 
neuroendocrine carcinomas) 
 - Thyroid origin  
- Pulmonary origin  - Thymic origin  
- Gastrointestinal origin  
- Pancreatic origin  
- Ovarian origin  
- Parathyroid adenoma  
- Pituitary adenoma  
- Pheochromocytoma  
Body cavity fluids 
- Lung origin 
(adenocarcinoma)  
 
- Genitourinary origin  
- Gastrointestinal origin  
- Breast origin  
- Ovarian origin  
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Concerning parafollicular cells, NKX2-1 expression 
can be found in normal and hyperplastic c-cells, as well 
as in medullary thyroid carcinomas. However, the 
signal intensity is much weaker and less homogenous 
than observed in tumors originating from follicular 
thyroid cells. 
Non-malignant branchiogenic cysts can easily be 
confounded with papillary thyroid carcinomas. Since 
positive immunostaining for NKX2-1 has been found 
in a subset of these non-malignant cervical cysts, 
NKX2-1 cannot serve to distinguish between both 
entities. 
Oncogenesis 
NKX2-1 is expressed in most differentiated thyroid 
neoplasms, but not in undifferentiated tumors of 
thyroid origin. On DNA-level, normal thyroids and 
papillary carcinomas do not exhibit DNA methylation 
in the CpG of NKX2-1 promoter, whereas 
undifferenciated thyroid carcinomas show DNA 
methylation in this region in about 60%. Most 
metastases of thyroid origin are positive for NKX2-1 
expression.  
A heterozygous germline mutation, which leads to a 
mutant NKX2-1 protein has been shown to be 
associated with increased cell proliferation. 
Consequently, it might contribute to a predisposition 
for multinodular goiter and papillary thyroid carcinoma 
(for details see section mutations). 
Neoplasms of the gastrointestinal tract 
Disease 
Small cell esophageal cancers exhibit NKX2-1 
expression in the majority of cases. In contrast, 
carcinoids originating from the gastrointestinal tract, 
such as ileal, appendical, duodenal, ampullary, rectal, 
pancreatic and gastric carcinoids are negative for 
NKX2-1 immunohistochemical staining. 
Neoplasms of the genitourinary tract 
Disease 
NKX2-1 seems to be implicated in neoplasms arising 
from the urinary system. Small cell carcinomas of the 
urinary bladder are positive for NKX2-1 staining in 25-
40% of cases. Likewise, large cell neuroendocrine 
bladder carcinomas exhibit NKX2-1 expression. In one 
study, 1/6 of a set of nephroblastomas showed nuclear 
positivity for NKX2-1, whereas metanephric adenomas 
and cystic nephromas were NKX2-1 negative. 
NKX2-1 expression can be found in benign tubal and 
endometrial epithelia, as well as in benign tumors 
originating from these tissues. In addition, malignant 
tumors of the female genital tract, such as endocervical 
adenocarcinomas, small cell carcinomas of the uterine 
cervix, endometrioid adenocarcinomas, serous 
carcinomas, clear cell carcinomas, and uterine 
malignant mixed Mullerian tumors show positivity for 
NKX2-1. Staining morphology in these tumors differs 
from rare positive cells to a diffusely positive staining 
pattern. 
Prognosis 
No correlation could be detected between positive 
NKX2-1 immunostaining in small cell carcinomas of 
the urinary bladder and clinicopathologic features 
(including outcome, age, sex, smoking history, stage 
and metastatic status). 
Neuroendocrine neoplasms 
Disease 
Among well-differentiated neuroendocrine tumors, 
only those tumors originating from the lung or thyroid 
are positive for NKX2-1 expression. Neither 
gastrointestinal typical or atypical carcinoids, nor 
neuroendocrine tumors from other sites (e.g. Merkel 
cell carcinomas, thymic carcinoids, ovarian large cell 
neuroendocrine carcinomas) show NKX2-1 expression. 
Concerning small cell carcinomas, NKX2-1 expression 
is not specific for small cell lung cancer, as NKX2-1 
expression can also be found in small cell carcinomas 
originating from the esophagus, prostate, bladder or 
uterine cervix. 
Neoplasms of neuroectodermal origin 
Disease 
NKX2-1 occasionally has been detected in 
glioblastoma multiforme and in ependymomas of the 
third ventricle. Other primary brain tumors, such as 
astrocytomas, oligodendrogliomas, medulloblastomas 
and gangliomas from various sites do not exhibit 
NKX2-1 expression. 
Sellar tumors, including pituicytomas, atypical 
pituicytomas, granular cell tumors and spindle cell 
oncocytomas can show positive immunostaining for 
NKX2-1. 
To be noted 
Note 
NKX2-1 has been well studied in neoplasms of the 
lung and thyroid, but lacks a sufficient level of 
evidence in other tumor entities. 
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